Zuo Tao, Jing Sha, Chen Peiru, Zhang Tao, Wang Yihao, Li Yanchang, Chang Lei, Rong Xingyu, Li Na, Zhao Zhenwen, Zhao Chao, Xu Ping
State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Beijing 102206, PR China.
MOE/NHC/CAMS Key Lab of Medical Molecular Virology, School of Basic Medical Sciences & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China.
J Proteomics. 2025 Jan 16;311:105358. doi: 10.1016/j.jprot.2024.105358. Epub 2024 Nov 22.
To date, the molecular pathogenic mechanisms between HBsAg and liver metabolic disorders have not been fully understood. To explore the overall effects of HBsAg on liver tissues from HBV transgenic mice, proteome, interactome, and signal pathway analysis were employed to uncover the underlying mechanisms. Bioinformatics analysis of 191 differentially expressed proteins suggested that HBV upregulated the expression of multiple enzymes involved in lipid synthesis, and small HBs (SHBs) caused lipid accumulation in cells. Further studies showed that SHBs bound to binding immunoglobulin protein (Bip), which normally functions in cell homeostasis against the unfolded protein response (UPR) signaling via occupying inositol-requiring enzyme 1 (IRE1). Hijacking Bip by SHBs alleviated the inhibition of post-endoplasmic reticulum (ER) signaling and sequential activation of the IRE1 downstream transcription factors involved in lipid synthesis, such as spliced X-box binding protein 1 (sXBP1) and sterol regulatory element-binding protein 1 (SREBP1), leading to lipid metabolism disorder. The restoration of Bip can alleviate ER stress, and block the sequential post-ER signaling caused by SHBs. This study revealed a new pathway through which SHBs promote lipid disorder, and suggests that Bip may serve as a novel target for intervention in HBV related liver diseases. SIGNIFICANCE: In this study, we found a new pathway promoting the lipid disorder by SHBs through quantitative proteomics studies, and Bip may serve as a novel target for intervention in HBV related liver diseases. These findings highlight a novel role of SHBs in regulating cell lipid metabolism and provide an insight into the relationship between HBV infection and liver fatty disorders, which may serve as a potential therapeutic target for intervention of HBV related liver diseases.
迄今为止,乙肝表面抗原(HBsAg)与肝脏代谢紊乱之间的分子致病机制尚未完全明确。为了探究HBsAg对乙肝病毒转基因小鼠肝脏组织的整体影响,我们采用蛋白质组学、相互作用组学和信号通路分析来揭示其潜在机制。对191种差异表达蛋白的生物信息学分析表明,乙肝病毒上调了多种参与脂质合成的酶的表达,而小分子乙肝表面抗原(SHBs)导致细胞内脂质积累。进一步研究表明,SHBs与结合免疫球蛋白蛋白(Bip)结合,Bip通常通过占据肌醇需求酶1(IRE1)在细胞内稳态中对抗未折叠蛋白反应(UPR)信号发挥作用。SHBs劫持Bip减轻了内质网(ER)后信号的抑制以及参与脂质合成的IRE1下游转录因子(如剪接的X盒结合蛋白1(sXBP1)和固醇调节元件结合蛋白1(SREBP1))的顺序激活,导致脂质代谢紊乱。恢复Bip可减轻内质网应激,并阻断由SHBs引起的内质网后信号传导。本研究揭示了SHBs促进脂质紊乱的新途径,并表明Bip可能作为干预乙肝相关肝病的新靶点。意义:在本研究中,我们通过定量蛋白质组学研究发现了SHBs促进脂质紊乱的新途径,且Bip可能作为干预乙肝相关肝病的新靶点。这些发现突出了SHBs在调节细胞脂质代谢中的新作用,并为乙肝病毒感染与肝脏脂肪紊乱之间的关系提供了见解,这可能作为干预乙肝相关肝病的潜在治疗靶点。